Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: A SEER population-based study

Benjamin M. Solomon, Kari G. Rabe, Susan L Slager, Jerry D. Brewer, James R Cerhan, Tait D. Shanafelt

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose Chronic lymphocytic leukemia (CLL) is associated with an increased risk of developing second cancers. However, it is unknown whether CLL alters the disease course of these cancers once they occur. Patients and Methods All patients with cancers of the breast (n = 579,164), colorectum (n = 412,366), prostate (n = 631,616), lung (n = 489,053), kidney (n = 95,795), pancreas (n = 82,116), and ovary (n = 61,937) reported to the SEER program from 1990 to 2007 were identified. Overall survival (OS; death resulting from any cause) and cancer-specific survival were examined, comparing patients with and without pre-existing CLL. Cancer-specific survival was evaluated for each tumor type in a site-specific manner (eg, death resulting from breast cancer in a patient with breast cancer). Results Patients with cancers of the breast (hazard ratio [HR], 1.70; P = .001), colorectum (HR, 1.65; P = .001), kidney (HR, 1.54; P = .001), prostate (HR, 1.92; P = .001), or lung (HR, 1.19; P = .001) had inferior OS if they had a pre-existing diagnosis of CLL after adjusting for age, sex, race, and disease stage. These results for OS remained significant for patients with cancers of the breast, colorectum, and prostate after excluding or censoring CLL-related deaths. Cancer-specific survival was also inferior for patients with cancers of the breast (HR, 1.41; P = .005) and colorectum (HR, 1.46; P = .001) who had pre-existing CLL after adjusting for age, sex, race, and disease stage. Conclusion Inferior OS and cancer-specific survival was observed for several common cancers in patients with pre-existing CLL. Additional studies are needed to determine the optimal management of these malignancies in patients with CLL and whether more aggressive screening or alternative approaches to adjuvant therapy are needed.

Original languageEnglish (US)
Pages (from-to)930-937
Number of pages8
JournalJournal of Clinical Oncology
Volume31
Issue number7
DOIs
StatePublished - Mar 1 2013

Fingerprint

Kidney Neoplasms
B-Cell Chronic Lymphocytic Leukemia
Colonic Neoplasms
Lung Neoplasms
Breast Neoplasms
Survival
Population
Neoplasms
Prostate
SEER Program
Kidney
Lung
Second Primary Neoplasms
Pancreas
Ovary
Prostatic Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia : A SEER population-based study. / Solomon, Benjamin M.; Rabe, Kari G.; Slager, Susan L; Brewer, Jerry D.; Cerhan, James R; Shanafelt, Tait D.

In: Journal of Clinical Oncology, Vol. 31, No. 7, 01.03.2013, p. 930-937.

Research output: Contribution to journalArticle

@article{e659679adcb84f78989079e604966e32,
title = "Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: A SEER population-based study",
abstract = "Purpose Chronic lymphocytic leukemia (CLL) is associated with an increased risk of developing second cancers. However, it is unknown whether CLL alters the disease course of these cancers once they occur. Patients and Methods All patients with cancers of the breast (n = 579,164), colorectum (n = 412,366), prostate (n = 631,616), lung (n = 489,053), kidney (n = 95,795), pancreas (n = 82,116), and ovary (n = 61,937) reported to the SEER program from 1990 to 2007 were identified. Overall survival (OS; death resulting from any cause) and cancer-specific survival were examined, comparing patients with and without pre-existing CLL. Cancer-specific survival was evaluated for each tumor type in a site-specific manner (eg, death resulting from breast cancer in a patient with breast cancer). Results Patients with cancers of the breast (hazard ratio [HR], 1.70; P = .001), colorectum (HR, 1.65; P = .001), kidney (HR, 1.54; P = .001), prostate (HR, 1.92; P = .001), or lung (HR, 1.19; P = .001) had inferior OS if they had a pre-existing diagnosis of CLL after adjusting for age, sex, race, and disease stage. These results for OS remained significant for patients with cancers of the breast, colorectum, and prostate after excluding or censoring CLL-related deaths. Cancer-specific survival was also inferior for patients with cancers of the breast (HR, 1.41; P = .005) and colorectum (HR, 1.46; P = .001) who had pre-existing CLL after adjusting for age, sex, race, and disease stage. Conclusion Inferior OS and cancer-specific survival was observed for several common cancers in patients with pre-existing CLL. Additional studies are needed to determine the optimal management of these malignancies in patients with CLL and whether more aggressive screening or alternative approaches to adjuvant therapy are needed.",
author = "Solomon, {Benjamin M.} and Rabe, {Kari G.} and Slager, {Susan L} and Brewer, {Jerry D.} and Cerhan, {James R} and Shanafelt, {Tait D.}",
year = "2013",
month = "3",
day = "1",
doi = "10.1200/JCO.2012.43.4449",
language = "English (US)",
volume = "31",
pages = "930--937",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia

T2 - A SEER population-based study

AU - Solomon, Benjamin M.

AU - Rabe, Kari G.

AU - Slager, Susan L

AU - Brewer, Jerry D.

AU - Cerhan, James R

AU - Shanafelt, Tait D.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Purpose Chronic lymphocytic leukemia (CLL) is associated with an increased risk of developing second cancers. However, it is unknown whether CLL alters the disease course of these cancers once they occur. Patients and Methods All patients with cancers of the breast (n = 579,164), colorectum (n = 412,366), prostate (n = 631,616), lung (n = 489,053), kidney (n = 95,795), pancreas (n = 82,116), and ovary (n = 61,937) reported to the SEER program from 1990 to 2007 were identified. Overall survival (OS; death resulting from any cause) and cancer-specific survival were examined, comparing patients with and without pre-existing CLL. Cancer-specific survival was evaluated for each tumor type in a site-specific manner (eg, death resulting from breast cancer in a patient with breast cancer). Results Patients with cancers of the breast (hazard ratio [HR], 1.70; P = .001), colorectum (HR, 1.65; P = .001), kidney (HR, 1.54; P = .001), prostate (HR, 1.92; P = .001), or lung (HR, 1.19; P = .001) had inferior OS if they had a pre-existing diagnosis of CLL after adjusting for age, sex, race, and disease stage. These results for OS remained significant for patients with cancers of the breast, colorectum, and prostate after excluding or censoring CLL-related deaths. Cancer-specific survival was also inferior for patients with cancers of the breast (HR, 1.41; P = .005) and colorectum (HR, 1.46; P = .001) who had pre-existing CLL after adjusting for age, sex, race, and disease stage. Conclusion Inferior OS and cancer-specific survival was observed for several common cancers in patients with pre-existing CLL. Additional studies are needed to determine the optimal management of these malignancies in patients with CLL and whether more aggressive screening or alternative approaches to adjuvant therapy are needed.

AB - Purpose Chronic lymphocytic leukemia (CLL) is associated with an increased risk of developing second cancers. However, it is unknown whether CLL alters the disease course of these cancers once they occur. Patients and Methods All patients with cancers of the breast (n = 579,164), colorectum (n = 412,366), prostate (n = 631,616), lung (n = 489,053), kidney (n = 95,795), pancreas (n = 82,116), and ovary (n = 61,937) reported to the SEER program from 1990 to 2007 were identified. Overall survival (OS; death resulting from any cause) and cancer-specific survival were examined, comparing patients with and without pre-existing CLL. Cancer-specific survival was evaluated for each tumor type in a site-specific manner (eg, death resulting from breast cancer in a patient with breast cancer). Results Patients with cancers of the breast (hazard ratio [HR], 1.70; P = .001), colorectum (HR, 1.65; P = .001), kidney (HR, 1.54; P = .001), prostate (HR, 1.92; P = .001), or lung (HR, 1.19; P = .001) had inferior OS if they had a pre-existing diagnosis of CLL after adjusting for age, sex, race, and disease stage. These results for OS remained significant for patients with cancers of the breast, colorectum, and prostate after excluding or censoring CLL-related deaths. Cancer-specific survival was also inferior for patients with cancers of the breast (HR, 1.41; P = .005) and colorectum (HR, 1.46; P = .001) who had pre-existing CLL after adjusting for age, sex, race, and disease stage. Conclusion Inferior OS and cancer-specific survival was observed for several common cancers in patients with pre-existing CLL. Additional studies are needed to determine the optimal management of these malignancies in patients with CLL and whether more aggressive screening or alternative approaches to adjuvant therapy are needed.

UR - http://www.scopus.com/inward/record.url?scp=84875712510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875712510&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.43.4449

DO - 10.1200/JCO.2012.43.4449

M3 - Article

C2 - 23341508

AN - SCOPUS:84875712510

VL - 31

SP - 930

EP - 937

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -